MEDI:GATE NEWS Daewoong Pharmaceutical’s patent lawsuit against generic sales…imposed a fine of 2.297 billion won
Medytox acquires shares of Daewoong Pharmaceutical’s U.S. partner Evolu, becoming the second largest shareholder
Daewoong Pharmaceutical, operating profit of 17 billion won last year… 62% decrease from the previous year
[금일 제약업계 주요기사] Celltrion antibody treatment’approved’… Bukwang Pharmaceutical “Corona 19 treatment, clinical phase 2 IND approval by the US FDA, etc.
Daewoong Pharmaceutical and LSK Global PS”Fight Son’ and Covid-19 treatment joint clinical development cooperation
Daewoong Pharmaceutical’s’Hoystar tablet’ approved for phase 3 clinical trials for COVID-19 prevention effect
![[BioS]Daewoong Pharmaceutical strengthens partnership with Ebolus “Expanding global sales channels”](https://img.etoday.co.kr/pto_db/2021/01/600/20210114093715_1568717_1200_675.jpg "[BioS]Daewoong Pharmaceutical strengthens partnership with Ebolus “Expanding global sales channels”")
![[특징주] Medytox,’upper limit’ on news of’US Botox dispute’ agreement](http://www.startuptoday.co.kr/news/photo/202102/69895_41261_5613.jpg "[특징주] Medytox,’upper limit’ on news of’US Botox dispute’ agreement")
![[금일 제약업계 주요기사] Celltrion antibody treatment’approved’… Bukwang Pharmaceutical “Corona 19 treatment, clinical phase 2 IND approval by the US FDA, etc.](https://www.youthdaily.co.kr/data/photos/20210205/art_16125110564763_e5e56c.jpg "[금일 제약업계 주요기사] Celltrion antibody treatment’approved’… Bukwang Pharmaceutical “Corona 19 treatment, clinical phase 2 IND approval by the US FDA, etc.")
